Clinical Trials – Metro Minnesota Community Oncology Research Consortium

Find Clinical Trials

Brain Breast Cancer Control Gastrointestinal Genitourinary Gynecology Head and Neck Hematology Lung Melanoma MNCCTN Sarcoma Other

Brain

November 29, 2022 in Brain

BN012

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NCT05438212)

September 14, 2022 in Brain

A071401

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS

June 30, 2022 in Brain

EAF151

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

June 30, 2022 in Brain

CE.7

A phase III trial of stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases.

June 30, 2022 in Brain

BN011

BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma (NCT 05095376)

June 30, 2022 in Brain

BN003

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

See All

Breast

May 31, 2023 in Breast

EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 (NCT05554354)

October 26, 2022 in Breast

evERA ML43171

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR…

August 16, 2022 in Breast

S2007

S2007: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases (NCT 04647916)

July 11, 2022 in Breast

S1706

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

July 11, 2022 in Breast

S1703

S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

July 1, 2022 in Breast

MA-39

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)

See All

Cancer Control / CCDR

May 10, 2023 in Cancer Control / CCDR

S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer…

April 18, 2023 in Cancer Control / CCDR

CC010

A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

December 19, 2022 in Cancer Control / CCDR

A212102

A212102 Blinded Reference Set For Multicancer Early Detection Blood Tests

November 30, 2022 in Cancer Control / CCDR

S2108CD

A CLUSTER RANDOMIZED TRIAL COMPARING AN EDUCATIONALLY ENHANCED GENOMIC TUMOR BOARD (EGTB) INTERVENTION TO USUAL PRACTICE TO INCREASE EVIDENCE-BASED GENOME-INFORMED THERAPY

November 22, 2022 in Cancer Control / CCDR

U21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

September 14, 2022 in Cancer Control / CCDR

A231602CD

Improving surgical care and outcomes in Older cancer Patients Through Implementation of an efficient pre-Surgical toolkit (OPTI-Surg)

See All

Gastrointestinal

May 31, 2023 in Gastrointestinal (GI)

A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)

April 24, 2023 in Gastrointestinal (GI)

A022102

A022102: A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

March 8, 2023 in Gastrointestinal (GI)

A022104

The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

February 14, 2023 in Gastrointestinal (GI)

EA2192: APOLLO

A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

October 20, 2022 in Gastrointestinal (GI)

Actuate 1801

Study Protocol 1801, Part 3 Arm B: Randomized Phase 2 Study of Gemcitabine/Nab-Paclitaxel Plus 9-ING-41 in Patients with Previously Untreated Metastatic Pancreatic Cancer

October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…

See All

Genitourinary

February 14, 2023 in Genitourinary (GU)

S2011

Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL

December 14, 2022 in Genitourinary (GU)

S2200

A Phase II Randomized Trial of Cabozantinib With or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)

October 14, 2022 in Genitourinary (GU)

CAPItello-280

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer…

October 11, 2022 in Genitourinary (GU)

GU012

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (NCT# 05327686)

September 21, 2022 in Genitourinary (GU)

A032101

A phase 2 trial of ADT interruption in patients responding exceptionally to AR pathway inhibitor in metastatic hormone-sensitive prostate cancer (MHSPC): A-DREAM NCT #05241860

August 26, 2022 in Genitourinary (GU)

EA8191

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (NCT04423211)

See All

Gynecology

May 31, 2023 in Gynecology

EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial (NCT# 05554328)

April 24, 2023 in Gynecology

A092104

A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy

September 21, 2022 in Gynecology

GY026

A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma…

June 30, 2022 in Gynecology

GY019

GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

June 30, 2022 in Gynecology

GY014

GY014: A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

June 30, 2022 in Gynecology

GY012

Olaparib, Cediranib Maleate, and Wee1 Inhibitor AZD1775 in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

See All

Head and Neck

March 27, 2023 in Head and Neck

HN010

A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer (NCT05408845)

September 14, 2022 in Head and Neck

EA3202

EA3202: A Phase II/III trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

July 1, 2022 in Head and Neck

HN009

HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell…

July 1, 2022 in Head and Neck

HN001

HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

June 30, 2022 in Head and Neck

EA3191

EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

June 30, 2022 in Head and Neck

EA3161

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

See All

Hematology

November 9, 2022 in Hematology

EA9152

A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

September 14, 2022 in Hematology

S1803

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct…

July 11, 2022 in Hematology

S1925

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small…

July 11, 2022 in Hematology

S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

June 30, 2022 in Hematology

EAA181

EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (NCT04566328)

June 30, 2022 in Hematology

EAA173

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

See All

Lung

April 3, 2023 in Lung

S2302

Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care for Advanced Non-Small Cell Lung Cancer Following Immunotherapy

December 20, 2022 in Lung

HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide)…

October 24, 2022 in Lung

S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib (LY3527723) In Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease…

September 15, 2022 in Lung

EMERGE-402

EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

September 14, 2022 in Lung

LungMAP

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

September 14, 2022 in Lung

EA5162

EA5162: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

See All

Melanoma

August 16, 2022 in Melanoma

A091903

A091903: A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma (NCT05111574)

July 11, 2022 in Melanoma

S2000

S2000: A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases

June 30, 2022 in Melanoma

EA6141

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

June 30, 2022 in Melanoma

A091802

A091802: Phase II randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma of the skin (cSCC

See All

MNCCTN

December 1, 2022 in MNCCTN

EH21C1 (MNCCTN027)

Topical cannabidiol (CBD) for the treatment of chemotherapy-induced peripheral neuropathy: a randomized placebo-controlled pilot trial

December 1, 2022 in MNCCTN

EH21C1 (MNCCTN024)

A Prospective, Randomized Study To Evaluate The Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12 Weeks

See All

Sarcoma

See All

Other Sites

May 10, 2023 in Other Sites

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

September 7, 2022 in Other Sites

TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL

August 31, 2022 in Other Sites

APL-101-01

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met…

July 11, 2022 in Other Sites

U19075

U19075: Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

July 11, 2022 in Other Sites

S2012

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

July 11, 2022 in Other Sites

S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

See All